💊 Mankind Pharma (#Mankind #MankindPharma) Q3FY25

🔹 Solid revenue growth (+24% YoY) & market share gains!
🔹 Acquisition costs weigh on profitability.
📊 Revenue: ₹3230 Cr (vs ₹2607 Cr YoY, ₹3076 Cr Q2)
💼 EBITDA: ₹895 Cr (+46% YoY)
📉 PAT: ₹385 Cr (vs ₹460 Cr YoY, ₹658 Cr Q2)

📌 High finance & depreciation costs impacting the bottom line.
#Earnings #Pharma #StockMarket
#Mankind #MankindPharma